Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698784 | 1.00 | CYP2A6 (0.42) | CYP2A6ERN1PTGS1PTGS2ACHE | |
| SCHEMBL96269 | 0.82 | ERN1 (0.41) | CYP2A6ERN1PTGS1PTGS2NFE2L2 | |
| SCHEMBL3129625 | 0.82 | CYP2A6 (0.52) | CYP2A6ERN1PTGS2SRCKDM4E | |
| SCHEMBL280640 | 0.82 | CYP2A6 (0.52) | CYP2A6ERN1SRCALDH1A1 | |
| SCHEMBL6854243 | 0.82 | ERN1 (0.41) | CYP2A6ERN1PTGS1PTGS2NFE2L2 | |
| Hydrochloric Acid SCHEMBL28065211 | 0.79 | CYP2A6 (0.50) | CYP2A6ERN1SRCALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL13735346 | 0.79 | ERN1 (0.39) | CYP2A6ERN1PTGS1PTGS2NFE2L2 | |
| SCHEMBL18255047 | 0.79 | GABBR2 (0.42) | PTGS1PTGS2ACHENFE2L2KDM4E | |
| SCHEMBL16954930 | 0.76 | PTGS1 (0.42) | PTGS1PTGS2ACHENFE2L2RAPGEF4 | |
| SCHEMBL16959668 | 0.76 | TP53 (0.46) | PTGS1PTGS2ACHENFE2L2RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2025-10-16 | — | — | US | disclosed |
| WO-2025122979-A1 | COMPOUNDS FOR SEROTONIN RECEPTOR ACTIVATION AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | ATAI THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4536640-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023236920-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-12-14 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, SMN1; SMN2, ADRM1 | CYP2A6 4825/4885ERN1 965/4885PTGS1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.